Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial

Dennis F. Moore, Thomas D. Brown, Michael LeBlanc, Steve Dahlberg, Thomas P. Miller, Suzanne McClure, Richard I. Fisher

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalInvestigational New Drugs
Issue number2
StatePublished - 1999


  • Menogaril
  • Non-Hodgkin's lymphoma
  • Southwest Oncology Group

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial'. Together they form a unique fingerprint.

Cite this